Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs

A. Végh, L. Szekeres, J. Parratt

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Bradykinin in a dose (25 ng kg-1 min-1) which did not alter coronary flow, or saline, were infused into a small branch of the left anterior descending coronary artery in dogs anaesthetized with chloralose and urethane, for 10 min prior to coronary artery occlusion and throughout the 25 min occlusion period. The degree of inhomogeneity of conduction and epicardial ST-segment changes were measured in the ischaemic zone with a composite electrode. In control dogs, coronary artery occlusion led to severe arrhythmias with an incidence of ventricular fibrillation of 47% and tachycardia of 80% and with a mean of 528 ± 140 ventricular premature beats. In marked contrast, those dogs administered bradykinin had no ventricular fibrillation or tachycardia and the number of premature beats was significantly less (53 ± 19). ST-segment changes were also much less in these dogs. These results raise the possibility that bradykinin might contribute to the protective effects of preconditioning and acts as an 'endogenous myocardial protective substance'.

Original languageEnglish
Pages (from-to)294-295
Number of pages2
JournalBritish Journal of Pharmacology
Volume104
Issue number2
Publication statusPublished - 1991

Fingerprint

Bradykinin
Cardiac Arrhythmias
Ischemia
Dogs
Coronary Vessels
Coronary Occlusion
Ventricular Fibrillation
Ventricular Tachycardia
Premature Cardiac Complexes
Chloralose
Ventricular Premature Complexes
Urethane
Electrodes
Incidence

Keywords

  • arrhythmias
  • bradykinin
  • myocardial ischaemia
  • reperfusion preconditioning
  • ST-segment changes
  • ventricular fibrillation

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{1f933a6128a14f129902395ea8a22ed8,
title = "Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs",
abstract = "Bradykinin in a dose (25 ng kg-1 min-1) which did not alter coronary flow, or saline, were infused into a small branch of the left anterior descending coronary artery in dogs anaesthetized with chloralose and urethane, for 10 min prior to coronary artery occlusion and throughout the 25 min occlusion period. The degree of inhomogeneity of conduction and epicardial ST-segment changes were measured in the ischaemic zone with a composite electrode. In control dogs, coronary artery occlusion led to severe arrhythmias with an incidence of ventricular fibrillation of 47{\%} and tachycardia of 80{\%} and with a mean of 528 ± 140 ventricular premature beats. In marked contrast, those dogs administered bradykinin had no ventricular fibrillation or tachycardia and the number of premature beats was significantly less (53 ± 19). ST-segment changes were also much less in these dogs. These results raise the possibility that bradykinin might contribute to the protective effects of preconditioning and acts as an 'endogenous myocardial protective substance'.",
keywords = "arrhythmias, bradykinin, myocardial ischaemia, reperfusion preconditioning, ST-segment changes, ventricular fibrillation",
author = "A. V{\'e}gh and L. Szekeres and J. Parratt",
year = "1991",
language = "English",
volume = "104",
pages = "294--295",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs

AU - Végh, A.

AU - Szekeres, L.

AU - Parratt, J.

PY - 1991

Y1 - 1991

N2 - Bradykinin in a dose (25 ng kg-1 min-1) which did not alter coronary flow, or saline, were infused into a small branch of the left anterior descending coronary artery in dogs anaesthetized with chloralose and urethane, for 10 min prior to coronary artery occlusion and throughout the 25 min occlusion period. The degree of inhomogeneity of conduction and epicardial ST-segment changes were measured in the ischaemic zone with a composite electrode. In control dogs, coronary artery occlusion led to severe arrhythmias with an incidence of ventricular fibrillation of 47% and tachycardia of 80% and with a mean of 528 ± 140 ventricular premature beats. In marked contrast, those dogs administered bradykinin had no ventricular fibrillation or tachycardia and the number of premature beats was significantly less (53 ± 19). ST-segment changes were also much less in these dogs. These results raise the possibility that bradykinin might contribute to the protective effects of preconditioning and acts as an 'endogenous myocardial protective substance'.

AB - Bradykinin in a dose (25 ng kg-1 min-1) which did not alter coronary flow, or saline, were infused into a small branch of the left anterior descending coronary artery in dogs anaesthetized with chloralose and urethane, for 10 min prior to coronary artery occlusion and throughout the 25 min occlusion period. The degree of inhomogeneity of conduction and epicardial ST-segment changes were measured in the ischaemic zone with a composite electrode. In control dogs, coronary artery occlusion led to severe arrhythmias with an incidence of ventricular fibrillation of 47% and tachycardia of 80% and with a mean of 528 ± 140 ventricular premature beats. In marked contrast, those dogs administered bradykinin had no ventricular fibrillation or tachycardia and the number of premature beats was significantly less (53 ± 19). ST-segment changes were also much less in these dogs. These results raise the possibility that bradykinin might contribute to the protective effects of preconditioning and acts as an 'endogenous myocardial protective substance'.

KW - arrhythmias

KW - bradykinin

KW - myocardial ischaemia

KW - reperfusion preconditioning

KW - ST-segment changes

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=0025947046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025947046&partnerID=8YFLogxK

M3 - Article

C2 - 1797297

AN - SCOPUS:0025947046

VL - 104

SP - 294

EP - 295

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -